dexmedetomidine has been researched along with Bone Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cheng, J; Gao, J; Jin, S; Le, C; Li, N; Liu, H; Yan, R | 1 |
| Chen, X; Wang, X; Xiao, J; Xu, Y | 1 |
| Wang, Q; Wu, J; Xu, M; Yuan, X | 1 |
| Aoe, T; Kozikowski, A; Neale, JH; Saito, O; Sarva, J; Yamamoto, T | 1 |
4 other study(ies) available for dexmedetomidine and Bone Cancer
| Article | Year |
|---|---|
Dexmedetomidine inhibits cell malignancy in osteosarcoma cells via miR-520a-3p-YOD1 interactome.
Topics: Analgesics, Non-Narcotic; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dexmedetomidine; Endopeptidases; Humans; MicroRNAs; Osteosarcoma; Signal Transduction; Thiolester Hydrolases | 2021 |
[ARTICLE WITHDRAWN] Dexmedetomidine Inhibits Osteosarcoma Cell Proliferation and Migration, and Promotes Apoptosis by Regulating miR-520a-3p.
Topics: Adrenergic alpha-2 Receptor Agonists; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Cell Movement; Cell Proliferation; Dexmedetomidine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Osteosarcoma; Tumor Cells, Cultured | 2018 |
The antinociceptive effect of systemic administration of a combination of low-dose tramadol and dexmedetomidine in a rat model of bone cancer pain.
Topics: Analgesics; Animals; Bone Neoplasms; Dexmedetomidine; Drug Therapy, Combination; Female; Pain, Intractable; Rats; Rats, Wistar; Tramadol | 2014 |
Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain.
Topics: Adrenergic alpha-Agonists; Analgesia; Animals; Bone Neoplasms; Dexmedetomidine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Ketamine; Male; Mice; Mice, Inbred C3H; Morphine; Pain, Intractable; Protease Inhibitors; Urea | 2006 |